Anticholinergic medications for the treatment of chronic obstructive pulmonary disease

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.

Original languageEnglish (US)
Pages (from-to)150-159
Number of pages10
JournalP and T
Volume32
Issue number3
StatePublished - Mar 2007
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Anticholinergic medications for the treatment of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this